Hampus Hillerstrom, New LuMind RDS President and CEO Has Strong Connections to Down Syndrome Research

Categories: Blog, Other
Hampus Hillerstrom
Hampus brings for-profit drug development expertise, science understanding and a personal passion to lead the organization’s expansion Marlborough, MA – [September 7, 2017] – LuMind™ Research Down Syndrome Foundation (LuMind RDS) announced today that Hampus Hillerstrom, the Board Vice Chair, has been appointed the organization’s next President and Chief Executive Officer. Hillerstrom joins LuMind from the …

Read More

Every Minute Counts: PBS Feature About Alzheimer’s in the US

Categories: Ds Research, Other
Watch Every Minute Counts on PBS
If you haven’t seen Every Minute Counts, the PBS documentary about Alzheimer’s disease in the United States, you should. Powerful personal stories combined with expert commentary paint a telling picture of the potential social and economic impact to this country unless a medical breakthrough for Alzheimer’s disease is discovered. In this post, we are sharing …

Read More

LuMind RDS Foundation Awards More Than $1.6 Million in New Grants for Cognition Research for Individuals with Down Syndrome

Categories: Ds Research, News
Person with Down syndrome celebrates
LuMind™ Research Down Syndrome Foundation (LuMind RDS) — formerly the Down Syndrome and Treatment Foundation and Research Down Syndrome — advances Down syndrome (Ds) cognition and Alzheimer’s disease (AD) research with $1,615,000 in funding awards for seven new research grants in 2017. Since 2004, LuMind RDS has raised more than $15 million and funded research …

Read More

Response to the Roche Clinical Trial for CLEMATIS

Categories: Blog, Ds Research, News
A response from LuMind Research Down Syndrome President and CEO Carolyn Cronin regarding the end of the Roche Clinical Trial for CLEMATIS. Hello friends, Like you we were disappointed to learn about the end of Roche Clinical Trial for CLEMATIS, the Phase II study investigating the efficacy and safety of basmisanil (RG1662) in adults and …

Read More

World’s First Clinical Trial for anti-Abeta Vaccine Targeting Alzheimer’s Disease-like Characteristics in People with Down Syndrome

Categories: Blog, Clinical Trials, Ds / Alzheimer's Connection, Ds Research, News
PRESS RELEASE – Issued by AC Immune Studies AC Immune’s ACI-24, the first anti-amyloid vaccine for treatment of Alzheimer’s disease-like characteristics in people with Down syndrome Clinical Study is done in collaboration with University of California San Diego US NIH provides significant funding with an additional grant from the LuMind Research Down Syndrome Foundation Alzheimer’s …

Read More